Catheter Precision (VTAK) announced that it has engaged a strategic advisor to formally market for sale its cardiac electrophysiology business. This strategic initiative is designed to create shareholder value by monetizing the company’s legacy medical device assets while sharpening its focus on the Flyte aviation platform.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTAK:
- Catheter Precision announces launch of Flyte Hops Florida
- Catheter Precision secures up to $88M in institutional financing commitments
- Morning News Wrap-Up 3/10/26: Tuesday’s Biggest Stock Market Stories!
- Why Is Catheter Precision Stock (VTAK) Up Today?
- Creatd sells remaining 80% of Fly Flyte to Catheter Precision